How Janssen Neuroscience is Addressing the Unmet Needs of Rare Disease Patients

Hong Sun, M.D., Ph.D. is a Senior Director, Global Compound Development Team Leader for the Neuroscience Therapeutic Area at Janssen Research & Development, LLC. In this segment, she discusses how Janssen is working to address the unmet needs of patients impacted by rare diseases, including rare neuromuscular conditions like myasthenia gravis (MG), through the Company’s autoantibody research. Janssen is currently investigating nipocalimab, which uses a unique mechanism of action to accelerate the removal of pathogenic autoantibody in patients affected by MG. 

Hong Sun, M.D., Ph.D., is the Global Development Lead for Nipocalimab. Hong is a neurologist by training and also has a Ph.D. in Neuroscience. As a strategic and passionate leader, she is devoted to the development of novel treatments to transform patient life suffering from neurological and psychiatric disorders. With over 15 years of pharmaceutical and biotech experience, Hong has broad development experience ranging from early, late phase clinical development and strategic team leadership with small molecules, biologics and drug-device combinations, in disease areas of Alzheimer’s Disease, sleep disorders, migraine, schizophrenia, myasthenia gravis, and other autoimmune diseases. She has also been a key contributor to the new drug application and approval for two first in class treatments: Belsomria (an orexin antagonist for insomnia), and Aimovig (a CGRP mAb for migraine).

Liked it? Take a second to support healthprofessionalradio on Patreon!

0 Comments

Leave a Reply

You must be logged in to post a comment.